Home/Filings/4/0000898432-23-000171
4//SEC Filing

Hwang Kuk Hyoun 4

Accession 0000898432-23-000171

CIK 0001840425other

Filed

Mar 26, 8:00 PM ET

Accepted

Mar 27, 4:09 PM ET

Size

7.9 KB

Accession

0000898432-23-000171

Insider Transaction Report

Form 4
Period: 2023-03-23
Hwang Kuk Hyoun
DirectorPresident and CEO10% Owner
Transactions
  • Other

    Common Stock

    2023-03-2320,0002,000,500 total(indirect: By LLC)
  • Other

    Warrant for Common Stock

    2023-03-2320,000370,000 total(indirect: By LLC)
    Exercise: $11.50Common Stock (20,000 underlying)
Footnotes (3)
  • [F1]Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor.
  • [F2]Represents the shares transferred by the Sponsor to Mr. David Jin Yoo for service as Chief Financial Officer.
  • [F3]Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. David Jin Yoo for his service as Chief Financial Officer. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments.

Documents

1 file

Issuer

Bellevue Life Sciences Acquisition Corp.

CIK 0001840425

Entity typeother

Related Parties

1
  • filerCIK 0001953660

Filing Metadata

Form type
4
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 4:09 PM ET
Size
7.9 KB